BR9708343A - Anticorpo composição linhagem de células método para determinar a presença de proteína de erbB3 e kit - Google Patents

Anticorpo composição linhagem de células método para determinar a presença de proteína de erbB3 e kit

Info

Publication number: BR9708343A
Authority: BR; Brazil
Prior art keywords: erbb3; kit; determining; erbb3 protein; cell line
Prior art date: 1996-03-27

Application number

BR9708343A

Other languages

English (en)

Inventor

Robert Akita

Mark Sliwkowski

Original Assignee

Genentech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-03-27

Filing date

1997-03-07

Publication date

1999-08-03

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24500380&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9708343(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1997-03-07 Application filed by Genentech Inc filed Critical Genentech Inc

1999-08-03 Publication of BR9708343A publication Critical patent/BR9708343A/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Oncology (AREA)
Immunology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Apparatus For Radiation Diagnosis (AREA)
Investigating Or Analysing Materials By Optical Means (AREA)

BR9708343A 1996-03-27 1997-03-07 Anticorpo composição linhagem de células método para determinar a presença de proteína de erbB3 e kit BR9708343A (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US62403696A	1996-03-27	1996-03-27
PCT/US1997/003546 WO1997035885A1 (en)	1996-03-27	1997-03-07	ErbB3 ANTIBODIES

Publications (1)

Publication Number	Publication Date
BR9708343A true BR9708343A (pt)	1999-08-03

Family

ID=24500380

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BR9708343A BR9708343A (pt)	1996-03-27	1997-03-07	Anticorpo composição linhagem de células método para determinar a presença de proteína de erbB3 e kit

Country Status (15)

Country	Link
EP (2)	EP1728802A3 (pt)
JP (1)	JP3925943B2 (pt)
CN (1)	CN1214044C (pt)
AT (1)	ATE342283T1 (pt)
AU (1)	AU727082B2 (pt)
BR (1)	BR9708343A (pt)
CA (1)	CA2246429C (pt)
DE (1)	DE69736806T3 (pt)
DK (1)	DK0896586T4 (pt)
ES (1)	ES2274537T5 (pt)
IL (2)	IL126303A (pt)
NZ (1)	NZ331360A (pt)
PT (1)	PT896586E (pt)
WO (1)	WO1997035885A1 (pt)
ZA (1)	ZA972554B (pt)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6417168B1 (en) *	1998-03-04	2002-07-09	The Trustees Of The University Of Pennsylvania	Compositions and methods of treating tumors
AUPQ105799A0 (en) *	1999-06-18	1999-07-08	Victor Chang Cardiac Research Institute, The	Cell growth inhibition
US6949245B1 (en)	1999-06-25	2005-09-27	Genentech, Inc.	Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US7041292B1 (en)	1999-06-25	2006-05-09	Genentech, Inc.	Treating prostate cancer with anti-ErbB2 antibodies
DE60042693D1 (de)	1999-08-27	2009-09-17	Genentech Inc	Dosierung für die behandlung mit anti erbb2-antikörpern
AU2008200654B2 (en) *	2001-08-09	2010-04-29	Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V.	Inhibitors of HER3 activity
EP1283053A1 (en) *	2001-08-09	2003-02-12	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	Inhibitors of HER3 activity
JP4660094B2 (ja)	2002-03-26	2011-03-30	ゼンサン（シャンハイ）サイ−テク．リミテッド	新生物を治療するためのＥｒｂＢ３に基づく方法および組成物
BR0312534A (pt)	2002-07-15	2007-03-13	Genentech Inc	método de identificação de um tumor, método para a identificação de células de tumor, método para prever a resposta de um indivìduo diagnosticado com um tumor de her2-positivo, método para a identificação de um individuo responsivo ao tratamento com anticorpo anti-her2 e métodos de tratamento de um paciente e artigo de manufatura
RU2404810C9 (ru)	2004-06-01	2015-06-20	Дженентек, Инк.	Конъюгаты антитело-лекарственное средство и способы
US20100111856A1 (en)	2004-09-23	2010-05-06	Herman Gill	Zirconium-radiolabeled, cysteine engineered antibody conjugates
WO2006034488A2 (en)	2004-09-23	2006-03-30	Genentech, Inc.	Cysteine engineered antibodies and conjugates
AR056857A1 (es)	2005-12-30	2007-10-24	U3 Pharma Ag	Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
CA2670522C (en)	2006-11-28	2018-08-07	U3 Pharma Gmbh	Activated her3 as a marker for predicting therapeutic efficacy
HRP20131113T1 (hr) *	2007-02-16	2014-01-17	Merrimack Pharmaceuticals, Inc.	Protutijela protiv erbb3 i njihova uporaba
AU2009281721A1 (en)	2008-08-15	2010-02-18	Merrimack Pharmaceuticals, Inc.	Methods and systems for predicting response of cells to a therapeutic agent
EP2417159A1 (en)	2009-04-07	2012-02-15	Roche Glycart AG	Bispecific anti-erbb-3/anti-c-met antibodies
SI3351558T1 (sl)	2009-11-13	2020-07-31	Daiichi Sankyo Europe Gmbh	Material in postopki za zdravljenje ali preprečevanje bolezni, povezanih s HER-3
KR20120123299A (ko)	2009-12-04	2012-11-08	제넨테크, 인크.	다중특이적 항체, 항체 유사체, 조성물 및 방법
US8859737B2 (en)	2009-12-22	2014-10-14	Roche Glycart Ag	Anti-HER3 antibodies and uses thereof
ES2535503T3 (es)	2010-03-11	2015-05-12	Merrimack Pharmaceuticals, Inc.	Uso de inhibidores de ErbB3 en el tratamiento del cáncer de mama triple negativo
RU2568051C2 (ru) *	2010-04-09	2015-11-10	Авео Фармасьютикалз, Инк.	АНТИТЕЛА К ErbB3
CA3051311A1 (en)	2010-05-27	2011-12-01	Genmab A/S	Monoclonal antibodies against her2
US9714294B2 (en)	2010-05-27	2017-07-25	Genmab A/S	Monoclonal antibodies against HER2 epitope
CA2803900A1 (en)	2010-07-09	2012-01-12	Exelixis, Inc.	Combinations of kinase inhibitors for the treatment of cancer
TW201302793A (zh)	2010-09-03	2013-01-16	Glaxo Group Ltd	新穎之抗原結合蛋白
EP3156421B1 (en) *	2010-11-01	2018-06-06	Symphogen A/S	Pan-her antibody composition
EP2699602B1 (en)	2011-04-19	2017-03-01	Merrimack Pharmaceuticals, Inc.	Bispecific anti-igf-1r and anti-erbb3 antibodies
CA2832389A1 (en)	2011-04-20	2012-10-26	Genmab A/S	Bispecific antibodies against her2 and cd3
US9273143B2 (en)	2011-09-30	2016-03-01	Regeneron Pharmaceuticals, Inc.	Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
ES2694153T3 (es)	2011-09-30	2018-12-18	Regeneron Pharmaceuticals, Inc.	Anticuerpos anti-ErbB3 y usos de los mismos
CN108753942A (zh) *	2011-10-06	2018-11-06	Aveo制药公司	预测肿瘤对抗erbb3抗体的应答
WO2013053076A1 (en)	2011-10-10	2013-04-18	Zensun （Shanghai）Science & Technology Limited	Compositions and methods for treating heart failure
AU2012335543C1 (en) *	2011-11-09	2017-12-14	Beijing Cotimes Biotech Co., Ltd.,	HER3 antibodies and uses thereof
KR102080535B1 (ko)	2011-11-23	2020-02-24	메디뮨 엘엘씨	Her3에 특이적인 결합 분자 및 이의 용도
UY34487A (es) *	2011-12-05	2013-07-31	Novartis Ag	Anticuerpos para receptor de factor de crecimiento epidérmico 3(her3)
KR20150064205A (ko)	2012-11-08	2015-06-10	에프. 호프만-라 로슈 아게	Her3의 베타-헤어핀에 결합하는 her3 항원 결합 단백질
CA2884429A1 (en) *	2012-11-08	2014-05-15	Birgit Bossenmaier	Anti-her3/her4 antigen binding proteins binding to the beta-hairpin of her3 and the beta-hairpin of her4
AR094403A1 (es)	2013-01-11	2015-07-29	Hoffmann La Roche	Terapia de combinación de anticuerpos anti-her3
WO2015048008A2 (en)	2013-09-24	2015-04-02	Medimmune, Llc	Binding molecules specific for her3 and uses thereof
WO2015100459A2 (en)	2013-12-27	2015-07-02	Merrimack Pharmaceuticals, Inc.	Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
US10745490B2 (en)	2014-04-11	2020-08-18	Celldex Therapeutics, Inc.	Anti-ErbB antibodies and methods of use thereof
BR112016024457A2 (pt)	2014-05-14	2018-01-23	Hoffmann La Roche	anticorpo isolado, imunoconjugado, uso do anticorpo, formulação farmacêutica, ácido nucleico isolado, célula hospedeira e método de produção de um anticorpo
US10184006B2 (en)	2015-06-04	2019-01-22	Merrimack Pharmaceuticals, Inc.	Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
TW202227504A (zh) *	2020-10-15	2022-07-16	大陸商上海翰森生物醫藥科技有限公司	抗ｅｒｂｂ３抗體或其抗原結合片段及其醫藥用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5183884A (en) *	1989-12-01	1993-02-02	United States Of America	Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
AU662311B2 (en) *	1991-02-05	1995-08-31	Novartis Ag	Recombinant antibodies specific for a growth factor receptor
EP0625200B1 (en) *	1992-02-06	2005-05-11	Chiron Corporation	Biosynthetic binding protein for cancer marker
AU4025193A (en) *	1992-04-08	1993-11-18	Cetus Oncology Corporation	Humanized C-erbB-2 specific antibodies
AU6527894A (en) *	1993-03-30	1994-10-24	Trustees Of The University Of Pennsylvania, The	Prevention of tumors with monoclonal antibodies against (neu)
US5783186A (en) *	1995-12-05	1998-07-21	Amgen Inc.	Antibody-induced apoptosis

1997
- 1997-03-07 IL IL12630397A patent/IL126303A/en not_active IP Right Cessation
- 1997-03-07 IL IL12630397D patent/IL126303A0/xx unknown
- 1997-03-07 PT PT97908923T patent/PT896586E/pt unknown
- 1997-03-07 CA CA002246429A patent/CA2246429C/en not_active Expired - Lifetime
- 1997-03-07 AU AU20711/97A patent/AU727082B2/en not_active Expired
- 1997-03-07 NZ NZ331360A patent/NZ331360A/xx not_active IP Right Cessation
- 1997-03-07 DK DK97908923.2T patent/DK0896586T4/en active
- 1997-03-07 BR BR9708343A patent/BR9708343A/pt not_active Application Discontinuation
- 1997-03-07 WO PCT/US1997/003546 patent/WO1997035885A1/en active IP Right Grant
- 1997-03-07 ES ES97908923.2T patent/ES2274537T5/es not_active Expired - Lifetime
- 1997-03-07 CN CNB971933588A patent/CN1214044C/zh not_active Expired - Lifetime
- 1997-03-07 EP EP06014174A patent/EP1728802A3/en not_active Withdrawn
- 1997-03-07 AT AT97908923T patent/ATE342283T1/de active
- 1997-03-07 JP JP53441197A patent/JP3925943B2/ja not_active Expired - Lifetime
- 1997-03-07 DE DE69736806.8T patent/DE69736806T3/de not_active Expired - Lifetime
- 1997-03-07 EP EP97908923.2A patent/EP0896586B2/en not_active Expired - Lifetime
- 1997-03-25 ZA ZA972554A patent/ZA972554B/xx unknown

Also Published As

Publication number	Publication date
DE69736806T2 (de)	2007-08-09
AU2071197A (en)	1997-10-17
EP1728802A2 (en)	2006-12-06
AU727082B2 (en)	2000-11-30
CN1214044C (zh)	2005-08-10
CA2246429A1 (en)	1997-10-02
ES2274537T3 (es)	2007-05-16
EP1728802A3 (en)	2006-12-13
DE69736806D1 (de)	2006-11-23
DE69736806T3 (de)	2015-10-08
DK0896586T4 (en)	2015-08-24
EP0896586B2 (en)	2015-05-20
CN1214695A (zh)	1999-04-21
ZA972554B (en)	1998-09-25
EP0896586B1 (en)	2006-10-11
DK0896586T3 (da)	2007-02-19
PT896586E (pt)	2007-01-31
ATE342283T1 (de)	2006-11-15
NZ331360A (en)	2000-03-27
IL126303A (en)	2002-05-23
IL126303A0 (en)	1999-05-09
WO1997035885A1 (en)	1997-10-02
JP3925943B2 (ja)	2007-06-06
JP2000508526A (ja)	2000-07-11
EP0896586A1 (en)	1999-02-17
CA2246429C (en)	2007-07-24
ES2274537T5 (es)	2015-09-14

Publication	Publication Date	Title
BR9708343A (pt)	1999-08-03	Anticorpo composição linhagem de células método para determinar a presença de proteína de erbB3 e kit
DE69939820D1 (de)	2008-12-11	Internalisierende erbb2 antikörper
EP0930366A3 (en)	1999-07-28	Binding domains in delta proteins
DE69429925D1 (de)	2002-03-28	METHODE ZUR BINDUNG VON MATERIAL AN DAS Beta-AMYLOID-PEPTID
BR9712410A (pt)	1999-10-19	Anticorpo isolado, composição, ácido nucleico, vetor, célula hospedeira, método para fazer um anticorpo anti-erbb2, método para a determinação da presença de erbb2, kit, método paa a indução da morte celular e artigo manufaturado
ATE213837T1 (de)	2002-03-15	Polypeptid-dendrimer komplexe
EP0942959A4 (en)	2005-04-13	NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
RS54049B1 (en)	2015-10-30	Sclerostin binding agents
DE60334141D1 (de)	2010-10-21	VERÄNDERUNG VON FcRn-BINDUNGSAFFINITÄTEN ODER VON SERUMHALBWERTSZEITEN VON ANTIKÖRPERN MITTELS MUTAGENESE
PT1135498E (pt)	2008-04-30	Variantes de anticorpos com maior afinidade de ligação em comparação com os anticorpos parentais
AU2152299A (en)	1999-05-24	Multivalent antigen-binding proteins
WO2001040307A8 (de)	2002-01-10	Antikörper gegen signal-regulator-proteine
WO2002090983A3 (de)	2003-09-12	Quantitaver einschritt immuntest in lyophilisierter form
IL154000A (en)	2010-02-17	A method that uses antibodies to diagnose arthritis
NZ336781A (en)	2002-10-25	Fibronectin binding protein compositions, antibodies thereto, and methods of use
WO2023060278A3 (en)	2023-07-06	Tibtech methods and compositions for detecting cdh17
WO1999025734A3 (en)	1999-07-15	Th2 CELL DEPLETION; COMPOSITIONS; METHODS
AU5326198A (en)	1998-06-29	Synthetic biepitope compounds which can be used as standards in the biological assays of troponin I
AU2726388A (en)	1989-07-05	Determination method, use and components
CA2589421A1 (en)	1997-10-02	Erbb3 antibodies
WO1999024835A3 (en)	1999-07-22	An immunoassay for procollagen-iii-c-terminal propeptide
WO2006138694A3 (en)	2009-04-16	Rabbit monoclonal antibody against id1 protein
MXPA02011906A (es)	2004-09-06	Ensayo, equipo y procedimiento a base de esferas no lavables.
DE69220863D1 (de)	1997-08-21	Denaturierte transportproteine zur verbesserung von enzymgebundenen immunoassays (elisa)
Xu	1996	The interaction of phosphorylase kinase with glycogen phosphorylase.

Legal Events

Date	Code	Title	Description
2004-07-20	B06G	Technical and formal requirements: other requirements [chapter 6.7 patent gazette]	Free format text: SUSPENSAO DO ANDAMENTO DO PEDIDO DE PATENTE PARA QUE SEJA COMPLEMENTADA A RETRIBUICAO EQUIVALENTE AO PEDIDO DE EXAME DE 36 (TRINTA E SEIS) REIVINDICACOES, VISTO QUE A RETRIBUICAO PAGA ATRAVES DA PETICAO N SP003288, DE 20000131, REFERE-SE A 21 (VINTE E UMA) REIVINDICACOES.
2006-01-17	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2007-04-17	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2008-02-06	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2009-02-10	B09B	Patent application refused [chapter 9.2 patent gazette]	Free format text: DE ACORDO COM O ART. 37 DA LEI 9.279/96, INDEFIRO O PRESENTE PEDIDO COM BASE NOS ARTS. 24 E 25 DA LEI NO 9.279/96
2012-05-02	B09B	Patent application refused [chapter 9.2 patent gazette]	Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.